Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Convertible Debt (2018 - 2024)

Historic Convertible Debt for Abvc Biopharma (ABVC) over the last 7 years, with Q1 2024 value amounting to $872336.0.

  • Abvc Biopharma's Convertible Debt rose 266169.31% to $872336.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $872336.0, marking a year-over-year increase of 266169.31%. This contributed to the annual value of $886522.0 for FY2023, which is N/A changed from last year.
  • Per Abvc Biopharma's latest filing, its Convertible Debt stood at $872336.0 for Q1 2024, which was up 266169.31% from $886522.0 recorded in Q4 2023.
  • In the past 5 years, Abvc Biopharma's Convertible Debt registered a high of $3.3 million during Q2 2023, and its lowest value of $31587.0 during Q1 2023.
  • Moreover, its 4-year median value for Convertible Debt was $2.1 million (2020), whereas its average is $1.8 million.
  • Over the last 5 years, Abvc Biopharma's Convertible Debt had its largest YoY gain of 266169.31% in 2024, and its largest YoY loss of 266169.31% in 2024.
  • Abvc Biopharma's Convertible Debt (Quarter) stood at $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021, then plummeted by 64.54% to $886522.0 in 2023, then dropped by 1.6% to $872336.0 in 2024.
  • Its Convertible Debt was $872336.0 in Q1 2024, compared to $886522.0 in Q4 2023 and $1.7 million in Q3 2023.